Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.55 |
| ▸ | ENPEP | Q07075 | 12/20 | 0.37 |
| ▸ | ANPEP | P15144 | 6/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL29120022 | 0.97 | PTGS1 (0.52) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| SCHEMBL16269970 | 0.85 | — | — | |
| SCHEMBL1964879 | 0.83 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| SCHEMBL20657045 | 0.83 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| SCHEMBL25418591 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL11053789 | 0.81 | PTGS1 (0.52) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| Hydrochloric Acid SCHEMBL11053790 | 0.81 | PTGS1 (0.52) | PTGS1SLC7A11ENPEPANPEPMMP2 | |
| SCHEMBL8751954 | 0.81 | — | — | |
| SCHEMBL60257 | 0.81 | — | — | |
| SCHEMBL17966747 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429573-A1 | COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | Thiogenesis Therapeutics, Inc. (US) | 2019-01-23 | — | — | EP | claimed |
| WO-2017161318-A1 | COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | THIOGENESIS THERAPEUTICS, INC. (US) | 2017-09-21 | — | — | WO | claimed |
| US-5316767-A | Oligopeptide; water soluble, heat resistance, stability | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-05-31 | — | — | US | claimed |
| US-12569456-B2 | Methods for the treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250170253-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4534527-A2 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | Thiogenesis Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119630280-A | Compositions and methods for preventing, treating, inhibiting and/or eliminating phytopathogenic infestations and infections | 诺维信公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-3684418-B1 | COMPOUNDS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | THIOGENESIS THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-118924717-A | Methods for treating cysteamine-sensitive disorders | 硫创治疗公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-111683684-B | Methods for treating cysteamine-sensitive disorders | 硫创治疗公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118225951-A | Marker group for major depressive disorder and screening method and application thereof | 上海大学 | 2024-06-21 | — | — | CN | disclosed |
| US-20160296630-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | ENDOCYTE INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2015-10-22 | — | — | US | disclosed |
| EP-2919774-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | Endocyte, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| US-20140154702-A1 | Methods For Treating Cancer Using Combination Therapies | ENDOCYTE INC (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2014085575-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | ENDOCYTE, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014078484-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| CN-102834110-A | Methods and compositions using peroxiredoxin 1 (PRX1) as an adjuvant | HEALTH RESEARCH INC | 2012-12-19 | — | — | CN | disclosed |
| US-20120022161-A1 | ACETYCYSTEINE COMPOSITIONS AND METHODS OF USE THEREOF | CUMBERLAND PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-0399555-A2 | A feed composition for culturing fishes | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569456-B2 | Methods for the treatment of cysteamine sensitive disorders | SLC7A11, CTH, SLC19A1 | PTGS1 365/4885SLC7A11 1/4885ENPEP 80/4885 |
| US-20160296630-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | SLC7A11, CXCR2, TPX2 | PTGS1 304/4885SLC7A11 1/4885ENPEP 174/4885 |
| US-20250170253-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | PTGS1 3280/4885SLC7A11 187/4885ENPEP 6/4885 |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | PTGS1 3280/4885SLC7A11 187/4885ENPEP 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.